SecBot SecBot
6-K ·Filed Aug 13, 2026

PHAR

Pharming Group N.V.
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago SEC0001828316-26-000035
Notable filing: 6-K
Actionable Insight ▲ Bullish

Monitor for initial prescription data and revenue contribution from Japan in upcoming quarters. The pediatric expansion (ages 4-11) is a first globally and could drive incremental volume. Watch for regulatory decisions in other countries reviewing pediatric label expansion.

DirectionBullish
Confidencemedium
Horizonmonths

Joenja

▲ Bullish Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and commercializing (first FDA approval March 2023). Label expansion for children 4-11 approved September 2026 with new doses available October 2026. EU launch starting Germany Q3 2026.
Next catalyst
None dated

What to watchJoenja's commercial ramp is the key story, watch quarterly Joenja revenue growth, EU launch uptake (starting Germany Q3 2026), and the pending sNDA for lower-weight pediatric patients (13kg to <27kg) submitted July 30, 2026. Phase 3 topline data for ages 1-6 (trial NCT05693129, primary completion July 2026) and Phase 2 CVID data (expected Q4 2026) are potential catalysts. The stock's 52-week low of $9.62 vs. analyst mean target of $34.35 suggests deep value if Joenja execution holds, but the company also faces headwinds from RUCONEST decline and recent revenue guidance cuts.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$12.35
T+0 close · Aug 13, 2026 · via day close
Latest settled
−0.49%
T+60 · $12.29
Vs SPY
+4.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $12.35entry
  2. T+1 · 3mo ago −5.10%α −4.90% · $11.72
  3. T+5 · 3mo ago −5.43%α −3.46% · $11.68
  4. T+20 · 2mo ago −9.23%α −7.48% · $11.21
  5. T+60 · 11d ago −0.49%α +4.99% · $12.29
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+, following NHI drug price list inclusion. Japan is the first market where Joenja is available for children aged 4-11. This expands Pharming's global footprint into a new geography with a partner handling distribution, but no revenue or financial guidance was provided.

Key Facts

  • Joenja (leniolisib) commercially launched in Japan for APDS patients aged 4+
  • Japan is the first market where Joenja is available for children aged 4-11
  • Launch follows MHLW approval in March 2026 and NHI drug price list inclusion
  • OrphanPacific, Inc. is the Marketing Authorization Holder responsible for supply and distribution
  • Joenja is already approved in the U.S., U.K., EU, Australia, Israel, Canada, South Korea, and Saudi Arabia for patients 12+
  • Leniolisib is under regulatory review for pediatric patients in several other countries

Financial Impact

No financial terms disclosed; revenue impact from Japan launch is unquantified but represents a new commercial market for Joenja

revenue

Risk Factors

  • No revenue or pricing details disclosed for Japan launch
  • Japan is a small market for ultra-rare diseases (~1-2 per million prevalence for APDS)
  • Dependence on OrphanPacific for distribution and supply chain execution
  • Forward-looking statements with no hard financial guidance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001828316-26-000035
Document: 0001828316-26-000035-index-headers.html0001828316-26-000035
Document: 0001828316-26-000035-index.html0001828316-26-000035
Document: 0001828316-26-000035.txt0001828316-26-000035

Track record

18 reports on PHAR

Performance horizon

9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  2. Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
  3. Oct 27, 202620d ago 6-K Bullish 6/10 No price data
  4. Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
  5. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
  6. Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
  7. Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  8. Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
  9. Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
  10. Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026